Országos Korányi Tbc és Pulmonológiai Intézet

Recent papers from Országos Korányi Tbc és Pulmonológiai Intézet

1. KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
2. Four-Year Longitudinal Phenotyping of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A Single-Centre Cohort StudyJournal of Clinical Medicine · 2026
3. Biologic outcomes in severe asthma patients by smoking status: evidence from SHARPAmerican Journal of Respiratory and Critical Care Medicine · 2026
4. A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinomaImmuno-Oncology Technology · 2026
5. Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN TrialJournal of Clinical Oncology · 2026
6. Local Recurrence After Lung Segmentectomy—Risk Factors and Future Directions: A Contemporary ReviewCancers · 2026
7. Comparative assessment of intratumoral sunitinib distribution and therapeutic response in matched primary and metastatic tumor modelsEuropean Journal of Pharmacology · 2026
8. Development of experimental isolated lung perfusion model using surgically resected tumorous human lobesBMC Pulmonary Medicine · 2026
9. Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022)Pathology & Oncology Research · 2026
10. High-throughput acoustic FFPE proteomics reveals ATP5IF1-associated mitochondrial alterations in acral melanomaMolecular & Cellular Proteomics · 2026
11. Cancer Diagnoses and Deaths in Hungary, 2011–2023: Nationwide Trends Before, During, and After the COVID-19 PandemicCancers · 2026
12. The Complement System and Its Role in Eosinophilic Inflammation in Respiratory DiseasesBiomedicines · 2026
13. Practices in reporting incidental findings in lung cancer screening by low-dose CT: a European Survey of Radiologists by SOLACEInsights into Imaging · 2026
14. A phase 3 study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with immune checkpoint inhibitor (ICI) versus standard-of-care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress.Journal of Clinical Oncology · 2026
15. Phase 2 study of PFS in third-line immune checkpoint inhibitor–resistant advanced NSCLC treated with the telomere-targeting agent ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with ICI.Journal of Clinical Oncology · 2026
16. Guidance for chest-CT in children and adults with cystic fibrosis: A European perspective (part 2: special situations/respiratory complications)Respiratory Medicine · 2026
17. B111-05 Targeting P2ry2 Reprograms Tumor Immunity and Inhibits Tumor Growth in Kras- and Egfr-mutant Non-small Cell Lung CancerAmerican Journal of Respiratory and Critical Care Medicine · 2026
18. Immune-related markers define clinically relevant prognostic subgroups in thymic epithelial tumorsLung Cancer · 2026
19. MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural MesotheliomaDiagnostics · 2026
20. Abstract 2108: Proteomic insights into metastatic small cell lung cancer using patient derived xenograft models.Cancer Research · 2026